Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02320669 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
A Phase 3 study, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
NCT02320669 is a Phase 3 study that has completed, run by Seattle Children's Hospital. The registered enrollment target is 220 participants.
The verdict
NCT02320669, a Phase 3 study, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
Study Summary
This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine (Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease during cardiopulmonary bypass surgery. Funding Source - FDA OOPD.
Interventions
- DRUG Placebo
- DRUG Triostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2014-11 |
| Est. Completion | 2019-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02320669
The ClinicalTrials.gov registry entry for NCT02320669 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02320669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02320669 about?
NCT02320669 is a clinical study titled "Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass". This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine (Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease during cardiopulmonary bypass surgery. Funding Source - FDA OOPD.
What is the current status of trial NCT02320669?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2014-11. Estimated completion is 2019-10.
What interventions are being tested in trial NCT02320669?
The interventions under investigation include: Placebo (DRUG), Triostat (DRUG).
Who is sponsoring clinical trial NCT02320669?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.